Background  ||| S:24 E:43 ||| FW
Plasma  ||| S:43 E:50 ||| FW
membrane  ||| S:50 E:59 ||| FW
microparticles  ||| S:59 E:74 ||| FW
( ||| S:74 E:75 ||| -LRB-
MP ||| S:75 E:77 ||| NNP
)  ||| S:77 E:79 ||| -RRB-
of  ||| S:79 E:82 ||| IN
endothelial  ||| S:82 E:102 ||| JJ
origin  ||| S:102 E:109 ||| NNS
have  ||| S:109 E:114 ||| VBP
been  ||| S:114 E:119 ||| VBN
identified  ||| S:119 E:130 ||| VBN
in  ||| S:130 E:133 ||| IN
normal  ||| S:133 E:140 ||| JJ
human  ||| S:140 E:146 ||| JJ
blood  ||| S:146 E:152 ||| NN
[  ||| S:152 E:154 ||| -LRB-
1  ||| S:154 E:156 ||| CD
2  ||| S:156 E:158 ||| CD
3  ||| S:158 E:160 ||| CD
]  ||| S:160 E:170 ||| -RRB-
and  ||| S:170 E:174 ||| CC
increased  ||| S:174 E:184 ||| JJ
counts  ||| S:184 E:191 ||| NNS
of  ||| S:191 E:194 ||| IN
MP  ||| S:194 E:197 ||| NNP
carrying  ||| S:197 E:206 ||| VBG
endothelial  ||| S:206 E:218 ||| JJ
antigens  ||| S:218 E:235 ||| NN
were  ||| S:235 E:240 ||| VBD
documented  ||| S:240 E:251 ||| VBN
in  ||| S:251 E:254 ||| IN
the  ||| S:254 E:258 ||| DT
blood  ||| S:258 E:264 ||| NN
of  ||| S:264 E:267 ||| IN
patients  ||| S:267 E:276 ||| NNS
with  ||| S:276 E:281 ||| IN
lupus  ||| S:281 E:295 ||| JJ
anticoagulant  ||| S:295 E:309 ||| NNS
[  ||| S:309 E:311 ||| -LRB-
1  ||| S:311 E:313 ||| LS
]  ||| S:313 E:315 ||| -RRB-
,  ||| S:315 E:317 ||| ,
acute  ||| S:317 E:323 ||| JJ
coronary  ||| S:323 E:332 ||| JJ
syndrome  ||| S:332 E:341 ||| NN
[  ||| S:341 E:343 ||| -LRB-
4  ||| S:343 E:345 ||| LS
]  ||| S:345 E:347 ||| -RRB-
,  ||| S:347 E:357 ||| ,
thrombotic  ||| S:357 E:368 ||| FW
thrombocytopenic  ||| S:368 E:385 ||| FW
purpura  ||| S:385 E:393 ||| FW
[  ||| S:393 E:395 ||| -LRB-
5  ||| S:395 E:397 ||| LS
]  ||| S:397 E:399 ||| -RRB-
or  ||| S:399 E:402 ||| CC
in  ||| S:402 E:405 ||| IN
patients  ||| S:405 E:422 ||| NNS
with  ||| S:422 E:427 ||| IN
exacerbated  ||| S:427 E:439 ||| JJ
multiple  ||| S:439 E:448 ||| JJ
sclerosis  ||| S:448 E:458 ||| NNS
[  ||| S:458 E:460 ||| -LRB-
6  ||| S:460 E:462 ||| CD
]  ||| S:462 E:464 ||| -RRB-
.  ||| S:464 E:466 ||| .
Similarly  ||| S:466 E:476 ||| RB
to  ||| S:476 E:487 ||| TO
blood  ||| S:487 E:493 ||| NN
platelets ||| S:493 E:502 ||| NN
,  ||| S:502 E:504 ||| ,
endothelial  ||| S:504 E:516 ||| JJ
cells  ||| S:516 E:522 ||| NNS
release  ||| S:522 E:530 ||| VBP
MP  ||| S:530 E:533 ||| NNP
which  ||| S:533 E:539 ||| WDT
express  ||| S:539 E:555 ||| VBP
phosphatidylserine  ||| S:555 E:574 ||| NNS
( ||| S:574 E:575 ||| -LRB-
PS ||| S:575 E:577 ||| NNP
)  ||| S:577 E:579 ||| -RRB-
on  ||| S:579 E:582 ||| IN
their  ||| S:582 E:588 ||| PRP$
surface ||| S:588 E:595 ||| NN
.  ||| S:595 E:597 ||| .
PS-exposing  ||| S:597 E:609 ||| NNP
MP  ||| S:609 E:612 ||| NNP
in  ||| S:612 E:623 ||| IN
blood  ||| S:623 E:629 ||| NN
appear  ||| S:629 E:636 ||| VBP
to  ||| S:636 E:639 ||| TO
act  ||| S:639 E:643 ||| VB
as  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
catalytic  ||| S:650 E:660 ||| JJ
surface  ||| S:660 E:668 ||| NN
for  ||| S:668 E:672 ||| IN
assembly  ||| S:672 E:689 ||| NN
of  ||| S:689 E:692 ||| IN
the  ||| S:692 E:696 ||| DT
prothrombinase  ||| S:696 E:711 ||| JJ
complex  ||| S:711 E:719 ||| NN
[  ||| S:719 E:721 ||| -LRB-
7  ||| S:721 E:723 ||| CD
]  ||| S:723 E:725 ||| -RRB-
.  ||| S:725 E:727 ||| .
Although  ||| S:727 E:736 ||| IN
circulating  ||| S:736 E:756 ||| VBG
MP  ||| S:756 E:759 ||| NNP
of  ||| S:759 E:762 ||| IN
various  ||| S:762 E:770 ||| JJ
cellular  ||| S:770 E:779 ||| JJ
origin  ||| S:779 E:786 ||| NN
in  ||| S:786 E:789 ||| IN
patient  ||| S:789 E:797 ||| NN
with  ||| S:797 E:802 ||| IN
sepsis  ||| S:802 E:809 ||| NN
were  ||| S:809 E:822 ||| VBD
reported  ||| S:822 E:831 ||| VBN
to  ||| S:831 E:834 ||| TO
be  ||| S:834 E:837 ||| VB
procoagulant  ||| S:837 E:850 ||| VBN
through  ||| S:850 E:858 ||| IN
multiple  ||| S:858 E:867 ||| JJ
mechanisms  ||| S:867 E:878 ||| NNS
[  ||| S:878 E:880 ||| -LRB-
8  ||| S:880 E:890 ||| CD
9  ||| S:890 E:892 ||| CD
]  ||| S:892 E:894 ||| -RRB-
,  ||| S:894 E:896 ||| ,
in  ||| S:896 E:899 ||| IN
healthy  ||| S:899 E:907 ||| JJ
individuals  ||| S:907 E:919 ||| NNS
they  ||| S:919 E:924 ||| PRP
may  ||| S:924 E:928 ||| MD
have  ||| S:928 E:933 ||| VB
an  ||| S:933 E:936 ||| DT
anticoagulant  ||| S:936 E:958 ||| JJ
function  ||| S:958 E:967 ||| NN
by  ||| S:967 E:970 ||| IN
promoting  ||| S:970 E:980 ||| VBG
the  ||| S:980 E:984 ||| DT
generation  ||| S:984 E:995 ||| NN
of  ||| S:995 E:998 ||| IN
low  ||| S:998 E:1002 ||| JJ
amounts  ||| S:1002 E:1010 ||| NNS
of  ||| S:1010 E:1021 ||| IN
thrombin  ||| S:1021 E:1030 ||| NN
that  ||| S:1030 E:1035 ||| IN
activate  ||| S:1035 E:1044 ||| JJ
protein  ||| S:1044 E:1052 ||| NN
C  ||| S:1052 E:1054 ||| NNP
[  ||| S:1054 E:1056 ||| -LRB-
2  ||| S:1056 E:1058 ||| LS
]  ||| S:1058 E:1060 ||| -RRB-
.  ||| S:1060 E:1070 ||| .
The  ||| S:1070 E:1074 ||| DT
process  ||| S:1074 E:1082 ||| NN
of  ||| S:1082 E:1085 ||| IN
membrane  ||| S:1085 E:1094 ||| JJ
vesiculation  ||| S:1094 E:1107 ||| NN
and  ||| S:1107 E:1111 ||| CC
MP-release  ||| S:1111 E:1122 ||| JJ
in  ||| S:1122 E:1133 ||| IN
platelets  ||| S:1133 E:1143 ||| NN
has  ||| S:1143 E:1147 ||| VBZ
been  ||| S:1147 E:1152 ||| VBN
shown  ||| S:1152 E:1158 ||| VBN
to  ||| S:1158 E:1161 ||| TO
require  ||| S:1161 E:1169 ||| VB
a  ||| S:1169 E:1171 ||| DT
calpain-dependent  ||| S:1171 E:1197 ||| JJ
dissociation  ||| S:1197 E:1210 ||| NN
of  ||| S:1210 E:1213 ||| IN
membrane  ||| S:1213 E:1222 ||| JJ
proteins  ||| S:1222 E:1231 ||| NNS
from  ||| S:1231 E:1236 ||| IN
the  ||| S:1236 E:1240 ||| DT
submembrane  ||| S:1240 E:1260 ||| JJ
cytoskeleton  ||| S:1260 E:1273 ||| NN
and  ||| S:1273 E:1277 ||| CC
most  ||| S:1277 E:1282 ||| RBS
likely  ||| S:1282 E:1289 ||| JJ
involves  ||| S:1289 E:1298 ||| NNS
intracellular  ||| S:1298 E:1320 ||| VBP
signaling  ||| S:1320 E:1330 ||| VBG
by  ||| S:1330 E:1333 ||| IN
platelet  ||| S:1333 E:1342 ||| JJ
protein  ||| S:1342 E:1350 ||| NN
kinases  ||| S:1350 E:1358 ||| NNS
[  ||| S:1358 E:1360 ||| -LRB-
10  ||| S:1360 E:1363 ||| CD
]  ||| S:1363 E:1365 ||| -RRB-
.  ||| S:1365 E:1367 ||| .
Besides  ||| S:1367 E:1383 ||| IN
platelets  ||| S:1383 E:1393 ||| JJ
stimulated  ||| S:1393 E:1404 ||| NN
by  ||| S:1404 E:1407 ||| IN
various  ||| S:1407 E:1415 ||| JJ
agonists  ||| S:1415 E:1424 ||| JJ
such  ||| S:1424 E:1429 ||| JJ
as  ||| S:1429 E:1432 ||| IN
thrombin  ||| S:1432 E:1449 ||| NN
with  ||| S:1449 E:1454 ||| IN
collagen  ||| S:1454 E:1463 ||| NN
or  ||| S:1463 E:1466 ||| CC
the  ||| S:1466 E:1470 ||| DT
complement  ||| S:1470 E:1481 ||| JJ
complex  ||| S:1481 E:1489 ||| JJ
C5b-9  ||| S:1489 E:1495 ||| NNP
[  ||| S:1495 E:1497 ||| -LRB-
7  ||| S:1497 E:1499 ||| CD
11  ||| S:1499 E:1502 ||| CD
]  ||| S:1502 E:1504 ||| -RRB-
,  ||| S:1504 E:1506 ||| ,
a  ||| S:1506 E:1516 ||| DT
release  ||| S:1516 E:1524 ||| NN
of  ||| S:1524 E:1527 ||| IN
PS-containing  ||| S:1527 E:1541 ||| JJ
membrane  ||| S:1541 E:1550 ||| JJ
MP  ||| S:1550 E:1553 ||| NNP
was  ||| S:1553 E:1557 ||| VBD
demonstrated  ||| S:1557 E:1570 ||| VBN
in  ||| S:1570 E:1581 ||| IN
other  ||| S:1581 E:1587 ||| JJ
cell  ||| S:1587 E:1592 ||| NN
types  ||| S:1592 E:1598 ||| NNS
such  ||| S:1598 E:1603 ||| JJ
as  ||| S:1603 E:1606 ||| IN
endotoxin-stimulated  ||| S:1606 E:1627 ||| JJ
monocytes  ||| S:1627 E:1637 ||| NNS
[  ||| S:1637 E:1647 ||| -LRB-
12  ||| S:1647 E:1650 ||| CD
]  ||| S:1650 E:1652 ||| -RRB-
,  ||| S:1652 E:1654 ||| ,
polymorphonuclear  ||| S:1654 E:1672 ||| NNS
leucocytes  ||| S:1672 E:1683 ||| VBP
stimulated  ||| S:1683 E:1694 ||| VBN
with  ||| S:1694 E:1699 ||| IN
the  ||| S:1699 E:1711 ||| DT
chemotactic  ||| S:1711 E:1723 ||| FW
peptide  ||| S:1723 E:1731 ||| FW
FMLP  ||| S:1731 E:1736 ||| FW
[  ||| S:1736 E:1738 ||| -LRB-
13  ||| S:1738 E:1741 ||| CD
]  ||| S:1741 E:1743 ||| -RRB-
or  ||| S:1743 E:1746 ||| CC
apoptotic  ||| S:1746 E:1756 ||| JJ
T-lymphocytes  ||| S:1756 E:1778 ||| NN
[  ||| S:1778 E:1780 ||| -LRB-
14  ||| S:1780 E:1783 ||| CD
]  ||| S:1783 E:1785 ||| -RRB-
.  ||| S:1785 E:1787 ||| .
The  ||| S:1787 E:1791 ||| DT
normal  ||| S:1791 E:1798 ||| JJ
restriction  ||| S:1798 E:1810 ||| NN
of  ||| S:1810 E:1813 ||| IN
PS  ||| S:1813 E:1816 ||| NNP
to  ||| S:1816 E:1819 ||| TO
the  ||| S:1819 E:1823 ||| DT
inner  ||| S:1823 E:1829 ||| JJ
surface  ||| S:1829 E:1845 ||| NN
of  ||| S:1845 E:1848 ||| IN
the  ||| S:1848 E:1852 ||| DT
plasma  ||| S:1852 E:1859 ||| JJ
membrane  ||| S:1859 E:1868 ||| NN
becomes  ||| S:1868 E:1876 ||| VBZ
perturbed  ||| S:1876 E:1886 ||| VBN
in  ||| S:1886 E:1889 ||| IN
apoptotic  ||| S:1889 E:1899 ||| JJ
cells  ||| S:1899 E:1913 ||| NNS
[  ||| S:1913 E:1915 ||| -LRB-
15  ||| S:1915 E:1918 ||| CD
16  ||| S:1918 E:1921 ||| CD
]  ||| S:1921 E:1923 ||| -RRB-
.  ||| S:1923 E:1925 ||| .
When  ||| S:1925 E:1930 ||| WRB
exposed ||| S:1930 E:1937 ||| VBN
,  ||| S:1937 E:1939 ||| ,
PS  ||| S:1939 E:1942 ||| NNP
is  ||| S:1942 E:1945 ||| VBZ
a  ||| S:1945 E:1947 ||| DT
determinant  ||| S:1947 E:1959 ||| NN
for  ||| S:1959 E:1963 ||| IN
phagocyte  ||| S:1963 E:1981 ||| JJ
recognition  ||| S:1981 E:1993 ||| NN
of  ||| S:1993 E:1996 ||| IN
cells  ||| S:1996 E:2002 ||| NNS
to  ||| S:2002 E:2005 ||| TO
be  ||| S:2005 E:2008 ||| VB
cleared ||| S:2008 E:2015 ||| VBN
.  ||| S:2015 E:2017 ||| .
Plasma  ||| S:2017 E:2024 ||| JJ
membrane  ||| S:2024 E:2041 ||| JJ
blebbing  ||| S:2041 E:2050 ||| NN
and  ||| S:2050 E:2054 ||| CC
MP-release  ||| S:2054 E:2065 ||| NNS
are  ||| S:2065 E:2069 ||| VBP
generally  ||| S:2069 E:2079 ||| RB
accepted  ||| S:2079 E:2088 ||| VBN
as  ||| S:2088 E:2091 ||| IN
typical  ||| S:2091 E:2107 ||| JJ
signs  ||| S:2107 E:2113 ||| NNS
of  ||| S:2113 E:2116 ||| IN
cell  ||| S:2116 E:2121 ||| NN
apoptosis  ||| S:2121 E:2131 ||| NNS
[  ||| S:2131 E:2133 ||| -LRB-
17  ||| S:2133 E:2136 ||| CD
]  ||| S:2136 E:2138 ||| -RRB-
.  ||| S:2138 E:2148 ||| .
In  ||| S:2148 E:2151 ||| IN
addition  ||| S:2151 E:2160 ||| NN
to  ||| S:2160 E:2163 ||| TO
a  ||| S:2163 E:2165 ||| DT
possible  ||| S:2165 E:2174 ||| JJ
pathophysiological  ||| S:2174 E:2193 ||| JJ
role  ||| S:2193 E:2198 ||| NN
of  ||| S:2198 E:2209 ||| IN
circulating  ||| S:2209 E:2221 ||| VBG
MP ||| S:2221 E:2223 ||| NNP
,  ||| S:2223 E:2225 ||| ,
analysis  ||| S:2225 E:2234 ||| NN
of  ||| S:2234 E:2237 ||| IN
MP  ||| S:2237 E:2240 ||| NNP
derived  ||| S:2240 E:2248 ||| VBD
from  ||| S:2248 E:2253 ||| IN
endothelial  ||| S:2253 E:2273 ||| JJ
cells  ||| S:2273 E:2279 ||| NNS
may  ||| S:2279 E:2283 ||| MD
be  ||| S:2283 E:2286 ||| VB
a  ||| S:2286 E:2288 ||| DT
valuable  ||| S:2288 E:2297 ||| JJ
diagnostic  ||| S:2297 E:2308 ||| JJ
marker  ||| S:2308 E:2315 ||| NN
of  ||| S:2315 E:2318 ||| IN
vessel  ||| S:2318 E:2325 ||| JJ
wall  ||| S:2325 E:2338 ||| NN
injury ||| S:2338 E:2344 ||| NN
.  ||| S:2344 E:2346 ||| .
The  ||| S:2346 E:2350 ||| DT
phospholipid-binding  ||| S:2350 E:2371 ||| JJ
protein  ||| S:2371 E:2379 ||| NN
annexin  ||| S:2379 E:2387 ||| VBD
V  ||| S:2387 E:2389 ||| NNP
has  ||| S:2389 E:2393 ||| VBZ
a  ||| S:2393 E:2403 ||| DT
high  ||| S:2403 E:2408 ||| JJ
affinity  ||| S:2408 E:2417 ||| NN
for  ||| S:2417 E:2421 ||| IN
PS  ||| S:2421 E:2424 ||| NNP
[  ||| S:2424 E:2426 ||| -LRB-
18  ||| S:2426 E:2429 ||| CD
]  ||| S:2429 E:2431 ||| -RRB-
and  ||| S:2431 E:2435 ||| CC
is  ||| S:2435 E:2438 ||| VBZ
utilized  ||| S:2438 E:2447 ||| VBN
in  ||| S:2447 E:2450 ||| IN
MP  ||| S:2450 E:2453 ||| NNP
detection  ||| S:2453 E:2471 ||| NN
in  ||| S:2471 E:2474 ||| IN
blood  ||| S:2474 E:2480 ||| NN
and  ||| S:2480 E:2484 ||| CC
in  ||| S:2484 E:2487 ||| IN
cell  ||| S:2487 E:2492 ||| NN
supernatants  ||| S:2492 E:2505 ||| NNS
[  ||| S:2505 E:2507 ||| -LRB-
1  ||| S:2507 E:2509 ||| LS
]  ||| S:2509 E:2511 ||| -RRB-
.  ||| S:2511 E:2513 ||| .
Since  ||| S:2513 E:2519 ||| IN
very  ||| S:2519 E:2524 ||| RB
little  ||| S:2524 E:2539 ||| RB
is  ||| S:2539 E:2542 ||| VBZ
known  ||| S:2542 E:2548 ||| VBN
about  ||| S:2548 E:2554 ||| IN
the  ||| S:2554 E:2558 ||| DT
mechanism  ||| S:2558 E:2568 ||| NN
of  ||| S:2568 E:2571 ||| IN
MP-release  ||| S:2571 E:2582 ||| JJ
from  ||| S:2582 E:2587 ||| IN
endothelial  ||| S:2587 E:2607 ||| JJ
cell ||| S:2607 E:2611 ||| NN
,  ||| S:2611 E:2613 ||| ,
it  ||| S:2613 E:2616 ||| PRP
is  ||| S:2616 E:2619 ||| VBZ
difficult  ||| S:2619 E:2629 ||| JJ
to  ||| S:2629 E:2632 ||| TO
judge  ||| S:2632 E:2638 ||| VB
the  ||| S:2638 E:2642 ||| DT
type  ||| S:2642 E:2647 ||| NN
and  ||| S:2647 E:2651 ||| CC
extent  ||| S:2651 E:2658 ||| NN
of  ||| S:2658 E:2669 ||| IN
endothelial  ||| S:2669 E:2681 ||| JJ
injury  ||| S:2681 E:2688 ||| NN
represented  ||| S:2688 E:2700 ||| VBD
by  ||| S:2700 E:2703 ||| IN
increased  ||| S:2703 E:2713 ||| JJ
plasma  ||| S:2713 E:2720 ||| NN
counts  ||| S:2720 E:2735 ||| NNS
of  ||| S:2735 E:2738 ||| IN
endothelial  ||| S:2738 E:2750 ||| JJ
MP ||| S:2750 E:2752 ||| NNP
.  ||| S:2752 E:2754 ||| .
We  ||| S:2754 E:2757 ||| PRP
used  ||| S:2757 E:2762 ||| VBD
flow  ||| S:2762 E:2767 ||| NN
cytometry  ||| S:2767 E:2777 ||| NN
to  ||| S:2777 E:2780 ||| TO
study  ||| S:2780 E:2786 ||| VB
the  ||| S:2786 E:2798 ||| DT
release  ||| S:2798 E:2806 ||| NN
of  ||| S:2806 E:2809 ||| IN
annexin  ||| S:2809 E:2817 ||| FW
V-binding  ||| S:2817 E:2827 ||| FW
membrane  ||| S:2827 E:2836 ||| FW
microparticles  ||| S:2836 E:2851 ||| FW
from  ||| S:2851 E:2864 ||| FW
cultured  ||| S:2864 E:2873 ||| FW
human  ||| S:2873 E:2879 ||| FW
umbilical  ||| S:2879 E:2889 ||| FW
vein  ||| S:2889 E:2894 ||| FW
endothelial  ||| S:2894 E:2906 ||| FW
cell  ||| S:2906 E:2911 ||| FW
( ||| S:2911 E:2912 ||| -LRB-
HUVEC ||| S:2912 E:2917 ||| NNP
)  ||| S:2917 E:2927 ||| -RRB-
stimulated  ||| S:2927 E:2938 ||| VBN
by  ||| S:2938 E:2941 ||| IN
various  ||| S:2941 E:2949 ||| JJ
agonists ||| S:2949 E:2957 ||| NN
.  ||| S:2957 E:2959 ||| .
We  ||| S:2959 E:2962 ||| PRP
further  ||| S:2962 E:2970 ||| RB
focused  ||| S:2970 E:2978 ||| VBN
our  ||| S:2978 E:2990 ||| PRP$
study  ||| S:2990 E:2996 ||| NN
on  ||| S:2996 E:2999 ||| IN
MP-release  ||| S:2999 E:3010 ||| JJ
from  ||| S:3010 E:3015 ||| IN
HUVEC  ||| S:3015 E:3021 ||| NNP
after  ||| S:3021 E:3027 ||| IN
proapoptotic  ||| S:3027 E:3048 ||| JJ
stimulation  ||| S:3048 E:3060 ||| NN
with  ||| S:3060 E:3065 ||| IN
the  ||| S:3065 E:3069 ||| DT
topoisomerase  ||| S:3069 E:3083 ||| NN
I  ||| S:3083 E:3085 ||| PRP
inhibitor  ||| S:3085 E:3095 ||| VBP
camptothecin  ||| S:3095 E:3116 ||| NNS
( ||| S:3116 E:3117 ||| -LRB-
CPT ||| S:3117 E:3120 ||| NNP
) ||| S:3120 E:3121 ||| -RRB-
.  ||| S:3121 E:3123 ||| .
Since  ||| S:3123 E:3129 ||| IN
CPT  ||| S:3129 E:3133 ||| NNP
analogues  ||| S:3133 E:3143 ||| VBD
become  ||| S:3143 E:3150 ||| VBN
one  ||| S:3150 E:3154 ||| CD
of  ||| S:3154 E:3157 ||| IN
the  ||| S:3157 E:3161 ||| DT
most  ||| S:3161 E:3166 ||| RBS
promising  ||| S:3166 E:3184 ||| JJ
new  ||| S:3184 E:3188 ||| JJ
classes  ||| S:3188 E:3196 ||| NNS
of  ||| S:3196 E:3199 ||| IN
antineoplastic  ||| S:3199 E:3214 ||| JJ
agents  ||| S:3214 E:3221 ||| NNS
introduced  ||| S:3221 E:3232 ||| VBN
into  ||| S:3232 E:3237 ||| IN
the  ||| S:3237 E:3249 ||| DT
clinic  ||| S:3249 E:3256 ||| NN
in  ||| S:3256 E:3259 ||| IN
recent  ||| S:3259 E:3266 ||| JJ
years  ||| S:3266 E:3272 ||| NNS
[  ||| S:3272 E:3274 ||| -LRB-
19  ||| S:3274 E:3277 ||| CD
]  ||| S:3277 E:3279 ||| -RRB-
,  ||| S:3279 E:3281 ||| ,
activity  ||| S:3281 E:3290 ||| NN
of  ||| S:3290 E:3293 ||| IN
camptothecin  ||| S:3293 E:3306 ||| NN
on  ||| S:3306 E:3317 ||| IN
endothelial  ||| S:3317 E:3329 ||| JJ
cells  ||| S:3329 E:3335 ||| NNS
may  ||| S:3335 E:3339 ||| MD
be  ||| S:3339 E:3342 ||| VB
of  ||| S:3342 E:3345 ||| IN
great  ||| S:3345 E:3351 ||| JJ
interest ||| S:3351 E:3359 ||| NN
.  ||| S:3359 E:3383 ||| .
Results  ||| S:3383 E:3410 ||| NNS
With  ||| S:3410 E:3415 ||| IN
the  ||| S:3415 E:3419 ||| DT
exception  ||| S:3419 E:3429 ||| NN
of  ||| S:3429 E:3432 ||| IN
high  ||| S:3432 E:3437 ||| JJ
concentration  ||| S:3437 E:3451 ||| NN
of  ||| S:3451 E:3464 ||| IN
ionophore  ||| S:3464 E:3474 ||| CD
A23187 ||| S:3474 E:3480 ||| CD
,  ||| S:3480 E:3482 ||| ,
rapid  ||| S:3482 E:3488 ||| JJ
stimulation  ||| S:3488 E:3500 ||| NN
of  ||| S:3500 E:3503 ||| IN
HUVEC  ||| S:3503 E:3509 ||| NNP
with  ||| S:3509 E:3514 ||| IN
various  ||| S:3514 E:3532 ||| JJ
agonists  ||| S:3532 E:3541 ||| NN
did  ||| S:3541 E:3545 ||| VBD
not  ||| S:3545 E:3549 ||| RB
result  ||| S:3549 E:3556 ||| VB
in  ||| S:3556 E:3559 ||| IN
a  ||| S:3559 E:3561 ||| DT
release  ||| S:3561 E:3569 ||| NN
of  ||| S:3569 E:3572 ||| IN
annexin  ||| S:3572 E:3580 ||| FW
V-binding  ||| S:3580 E:3600 ||| FW
microparticles  ||| S:3600 E:3625 ||| FW
Flow  ||| S:3625 E:3630 ||| FW
cytometry  ||| S:3630 E:3640 ||| FW
analysis  ||| S:3640 E:3649 ||| NN
of  ||| S:3649 E:3652 ||| IN
HUVEC  ||| S:3652 E:3658 ||| NNP
culture  ||| S:3658 E:3666 ||| NN
supernatant  ||| S:3666 E:3688 ||| VBZ
demonstrated  ||| S:3688 E:3701 ||| VBN
that  ||| S:3701 E:3706 ||| IN
a  ||| S:3706 E:3708 ||| DT
30  ||| S:3708 E:3711 ||| CD
min  ||| S:3711 E:3715 ||| JJ
treatment  ||| S:3715 E:3725 ||| NN
with  ||| S:3725 E:3730 ||| IN
10  ||| S:3730 E:3733 ||| CD
μM  ||| S:3733 E:3736 ||| JJ
ionophore  ||| S:3736 E:3756 ||| NNS
A23187  ||| S:3756 E:3763 ||| VBP
caused  ||| S:3763 E:3770 ||| VBN
the  ||| S:3770 E:3774 ||| DT
release  ||| S:3774 E:3782 ||| NN
of  ||| S:3782 E:3785 ||| IN
low  ||| S:3785 E:3789 ||| JJ
counts  ||| S:3789 E:3796 ||| NNS
of  ||| S:3796 E:3799 ||| IN
annexin  ||| S:3799 E:3817 ||| JJ
V-binding  ||| S:3817 E:3827 ||| JJ
MP  ||| S:3827 E:3830 ||| NNP
( ||| S:3830 E:3831 ||| -LRB-
Fig.  ||| S:3831 E:3836 ||| NNP
1A ||| S:3836 E:3838 ||| NNP
) ||| S:3838 E:3839 ||| -RRB-
.  ||| S:3839 E:3841 ||| .
Similar  ||| S:3841 E:3849 ||| JJ
short-time  ||| S:3849 E:3860 ||| JJ
activation  ||| S:3860 E:3871 ||| NN
of  ||| S:3871 E:3884 ||| IN
HUVEC  ||| S:3884 E:3890 ||| NNP
with  ||| S:3890 E:3895 ||| IN
phorbol  ||| S:3895 E:3903 ||| FW
myristate  ||| S:3903 E:3913 ||| FW
acetate  ||| S:3913 E:3921 ||| FW
( ||| S:3921 E:3922 ||| -LRB-
PMA ||| S:3922 E:3925 ||| NNP
)  ||| S:3925 E:3927 ||| -RRB-
( ||| S:3927 E:3928 ||| -LRB-
1  ||| S:3928 E:3930 ||| CD
μg ||| S:3930 E:3932 ||| CD
/ ||| S:3932 E:3933 ||| CD
mL ||| S:3933 E:3935 ||| NN
) ||| S:3935 E:3936 ||| -RRB-
,  ||| S:3936 E:3948 ||| ,
human  ||| S:3948 E:3954 ||| JJ
thrombin  ||| S:3954 E:3963 ||| FW
receptor  ||| S:3963 E:3972 ||| FW
activating  ||| S:3972 E:3983 ||| FW
peptide  ||| S:3983 E:3991 ||| FW
( ||| S:3991 E:3992 ||| -LRB-
TRAP ||| S:3992 E:3996 ||| NNP
)  ||| S:3996 E:3998 ||| -RRB-
1-50  ||| S:3998 E:4013 ||| FW
μmol ||| S:4013 E:4017 ||| FW
/ ||| S:4017 E:4018 ||| FW
L ||| S:4018 E:4019 ||| NNP
,  ||| S:4019 E:4021 ||| ,
human  ||| S:4021 E:4027 ||| JJ
thrombin  ||| S:4027 E:4036 ||| NNS
( ||| S:4036 E:4037 ||| -LRB-
THR ||| S:4037 E:4040 ||| NNP
)  ||| S:4040 E:4042 ||| -RRB-
0.1-10  ||| S:4042 E:4049 ||| NNP
NIH  ||| S:4049 E:4053 ||| NNP
Unit ||| S:4053 E:4057 ||| NNP
/ ||| S:4057 E:4058 ||| NNP
mL ||| S:4058 E:4060 ||| NNP
,  ||| S:4060 E:4062 ||| ,
human  ||| S:4062 E:4078 ||| JJ
tissue  ||| S:4078 E:4085 ||| NN
plasminogen  ||| S:4085 E:4097 ||| NN
activator  ||| S:4097 E:4107 ||| NNS
( ||| S:4107 E:4108 ||| -LRB-
TPA ||| S:4108 E:4111 ||| NNP
)  ||| S:4111 E:4113 ||| -RRB-
3.5  ||| S:4113 E:4117 ||| CD
kU ||| S:4117 E:4119 ||| JJ
/ ||| S:4119 E:4120 ||| NNP
mL  ||| S:4120 E:4123 ||| NNP
or  ||| S:4123 E:4126 ||| CC
human  ||| S:4126 E:4142 ||| JJ
angiotensin  ||| S:4142 E:4154 ||| JJ
II  ||| S:4154 E:4157 ||| NNP
( ||| S:4157 E:4158 ||| -LRB-
AGTII ||| S:4158 E:4163 ||| NNP
)  ||| S:4163 E:4165 ||| -RRB-
1  ||| S:4165 E:4167 ||| CD
μmol ||| S:4167 E:4171 ||| CD
/ ||| S:4171 E:4172 ||| CD
L  ||| S:4172 E:4174 ||| NNP
did  ||| S:4174 E:4178 ||| VBD
not  ||| S:4178 E:4182 ||| RB
cause  ||| S:4182 E:4188 ||| VB
any  ||| S:4188 E:4202 ||| DT
significant  ||| S:4202 E:4214 ||| JJ
increase  ||| S:4214 E:4223 ||| NN
in  ||| S:4223 E:4226 ||| IN
MP-release  ||| S:4226 E:4237 ||| NNP
( ||| S:4237 E:4238 ||| -LRB-
Fig.  ||| S:4238 E:4243 ||| NNP
1A ||| S:4243 E:4245 ||| NNP
) ||| S:4245 E:4246 ||| -RRB-
.  ||| S:4246 E:4248 ||| .
All  ||| S:4248 E:4252 ||| DT
of  ||| S:4252 E:4255 ||| IN
the  ||| S:4255 E:4269 ||| DT
agonists  ||| S:4269 E:4278 ||| NN
applied  ||| S:4278 E:4286 ||| VBD
induced  ||| S:4286 E:4294 ||| VBN
morphological  ||| S:4294 E:4308 ||| JJ
changes  ||| S:4308 E:4316 ||| NNS
in  ||| S:4316 E:4319 ||| IN
HUVEC  ||| S:4319 E:4335 ||| NNP
seen  ||| S:4335 E:4340 ||| VBN
by  ||| S:4340 E:4343 ||| IN
phase  ||| S:4343 E:4349 ||| NN
contrast  ||| S:4349 E:4358 ||| NN
light  ||| S:4358 E:4364 ||| NN
microscopy ||| S:4364 E:4374 ||| NN
,  ||| S:4374 E:4376 ||| ,
which  ||| S:4376 E:4382 ||| WDT
confirmed  ||| S:4382 E:4402 ||| VBD
the  ||| S:4402 E:4406 ||| DT
cellular  ||| S:4406 E:4415 ||| JJ
activation  ||| S:4415 E:4426 ||| NNS
( ||| S:4426 E:4427 ||| -LRB-
not  ||| S:4427 E:4431 ||| RB
shown ||| S:4431 E:4436 ||| VBN
) ||| S:4436 E:4437 ||| -RRB-
.  ||| S:4437 E:4467 ||| .
Proapoptotic ||| S:4467 E:4479 ||| NNP
,  ||| S:4479 E:4481 ||| ,
but  ||| S:4481 E:4485 ||| CC
not  ||| S:4485 E:4489 ||| RB
proinflammatory ||| S:4489 E:4504 ||| JJ
,  ||| S:4504 E:4506 ||| ,
stimulation  ||| S:4506 E:4528 ||| VBD
induced  ||| S:4528 E:4536 ||| VBN
a  ||| S:4536 E:4538 ||| DT
release  ||| S:4538 E:4546 ||| NN
of  ||| S:4546 E:4549 ||| IN
annexin  ||| S:4549 E:4557 ||| JJ
V-binding  ||| S:4557 E:4567 ||| JJ
microparticles  ||| S:4567 E:4592 ||| NN
from  ||| S:4592 E:4597 ||| IN
HUVEC  ||| S:4597 E:4613 ||| NNP
MP  ||| S:4613 E:4616 ||| NNP
count  ||| S:4616 E:4622 ||| NN
increased  ||| S:4622 E:4632 ||| VBD
overnight  ||| S:4632 E:4642 ||| JJ
in  ||| S:4642 E:4645 ||| IN
the  ||| S:4645 E:4649 ||| DT
media  ||| S:4649 E:4655 ||| NNS
of  ||| S:4655 E:4668 ||| IN
unstimulated  ||| S:4668 E:4681 ||| JJ
cell  ||| S:4681 E:4686 ||| NN
culture ||| S:4686 E:4693 ||| NN
,  ||| S:4693 E:4695 ||| ,
but  ||| S:4695 E:4699 ||| CC
this  ||| S:4699 E:4704 ||| DT
was  ||| S:4704 E:4708 ||| VBD
not  ||| S:4708 E:4712 ||| RB
enhanced  ||| S:4712 E:4721 ||| VBN
by  ||| S:4721 E:4734 ||| IN
TNFα  ||| S:4734 E:4739 ||| NNP
( ||| S:4739 E:4740 ||| -LRB-
1000  ||| S:4740 E:4745 ||| CD
U ||| S:4745 E:4746 ||| NNP
/  ||| S:4746 E:4748 ||| NNP
mL ||| S:4748 E:4750 ||| NNP
)  ||| S:4750 E:4752 ||| -RRB-
or  ||| S:4752 E:4755 ||| CC
by  ||| S:4755 E:4758 ||| IN
LPS  ||| S:4758 E:4762 ||| NNP
( ||| S:4762 E:4763 ||| -LRB-
10  ||| S:4763 E:4766 ||| CD
μg ||| S:4766 E:4768 ||| CD
/ ||| S:4768 E:4769 ||| CD
mL ||| S:4769 E:4771 ||| NN
) ||| S:4771 E:4772 ||| -RRB-
.  ||| S:4772 E:4774 ||| .
However ||| S:4774 E:4781 ||| RB
,  ||| S:4781 E:4783 ||| ,
when  ||| S:4783 E:4798 ||| WRB
cells  ||| S:4798 E:4804 ||| NNS
were  ||| S:4804 E:4809 ||| VBD
activated  ||| S:4809 E:4819 ||| VBN
with  ||| S:4819 E:4824 ||| IN
TNFα  ||| S:4824 E:4829 ||| JJ
in  ||| S:4829 E:4832 ||| IN
the  ||| S:4832 E:4836 ||| DT
presence  ||| S:4836 E:4845 ||| NN
of  ||| S:4845 E:4858 ||| IN
cycloheximide  ||| S:4858 E:4872 ||| NNS
( ||| S:4872 E:4873 ||| -LRB-
50  ||| S:4873 E:4876 ||| CD
μg ||| S:4876 E:4878 ||| CD
/ ||| S:4878 E:4879 ||| CD
mL ||| S:4879 E:4881 ||| NN
)  ||| S:4881 E:4883 ||| -RRB-
to  ||| S:4883 E:4886 ||| TO
promote  ||| S:4886 E:4894 ||| VB
apoptosis  ||| S:4894 E:4904 ||| NNS
[  ||| S:4904 E:4906 ||| -LRB-
20  ||| S:4906 E:4909 ||| CD
]  ||| S:4909 E:4911 ||| -RRB-
,  ||| S:4911 E:4913 ||| ,
a  ||| S:4913 E:4925 ||| DT
dramatic  ||| S:4925 E:4934 ||| JJ
increase  ||| S:4934 E:4943 ||| NN
in  ||| S:4943 E:4946 ||| IN
MP  ||| S:4946 E:4949 ||| NNP
count  ||| S:4949 E:4955 ||| NN
was  ||| S:4955 E:4959 ||| VBD
observed ||| S:4959 E:4967 ||| VBN
,  ||| S:4967 E:4969 ||| ,
as  ||| S:4969 E:4972 ||| RB
compared  ||| S:4972 E:4991 ||| VBN
to  ||| S:4991 E:4994 ||| TO
TNFα  ||| S:4994 E:4999 ||| JJ
or  ||| S:4999 E:5002 ||| CC
cycloheximide  ||| S:5002 E:5016 ||| JJ
treatment  ||| S:5016 E:5026 ||| NN
alone  ||| S:5026 E:5032 ||| RB
( ||| S:5032 E:5033 ||| -LRB-
Fig.  ||| S:5033 E:5038 ||| NNP
1B ||| S:5038 E:5040 ||| NNP
) ||| S:5040 E:5041 ||| -RRB-
.  ||| S:5041 E:5053 ||| .
Similarly ||| S:5053 E:5062 ||| RB
,  ||| S:5062 E:5064 ||| ,
induction  ||| S:5064 E:5074 ||| VBG
of  ||| S:5074 E:5077 ||| IN
apoptosis  ||| S:5077 E:5087 ||| NN
with  ||| S:5087 E:5092 ||| IN
5  ||| S:5092 E:5094 ||| CD
μM  ||| S:5094 E:5097 ||| JJ
CPT ||| S:5097 E:5100 ||| NNP
,  ||| S:5100 E:5102 ||| ,
a  ||| S:5102 E:5114 ||| DT
topoisomerase  ||| S:5114 E:5128 ||| NN
I  ||| S:5128 E:5130 ||| PRP
inhibitor  ||| S:5130 E:5140 ||| VBP
[  ||| S:5140 E:5142 ||| -LRB-
19  ||| S:5142 E:5145 ||| CD
]  ||| S:5145 E:5147 ||| -RRB-
,  ||| S:5147 E:5149 ||| ,
led  ||| S:5149 E:5153 ||| VBN
to  ||| S:5153 E:5156 ||| TO
a  ||| S:5156 E:5158 ||| DT
release  ||| S:5158 E:5166 ||| NN
of  ||| S:5166 E:5179 ||| IN
annexin  ||| S:5179 E:5187 ||| JJ
V-binding  ||| S:5187 E:5197 ||| JJ
MP  ||| S:5197 E:5200 ||| NNP
which  ||| S:5200 E:5206 ||| WDT
was  ||| S:5206 E:5210 ||| VBD
prevented  ||| S:5210 E:5220 ||| VBN
by  ||| S:5220 E:5223 ||| IN
ZVAD ||| S:5223 E:5227 ||| NNP
.  ||| S:5227 E:5229 ||| .
ZVAD  ||| S:5229 E:5244 ||| NNP
also  ||| S:5244 E:5249 ||| RB
inhibited  ||| S:5249 E:5259 ||| VBD
a  ||| S:5259 E:5261 ||| DT
release  ||| S:5261 E:5269 ||| NN
of  ||| S:5269 E:5272 ||| IN
MP  ||| S:5272 E:5275 ||| NNP
from  ||| S:5275 E:5280 ||| IN
unstimulated  ||| S:5280 E:5293 ||| JJ
cells ||| S:5293 E:5298 ||| NNS
,  ||| S:5298 E:5310 ||| ,
which  ||| S:5310 E:5316 ||| WDT
probably  ||| S:5316 E:5325 ||| RB
represents  ||| S:5325 E:5336 ||| VBZ
spontaneous  ||| S:5336 E:5348 ||| JJ
apoptosis  ||| S:5348 E:5358 ||| NN
of  ||| S:5358 E:5371 ||| IN
cultured  ||| S:5371 E:5380 ||| JJ
HUVEC  ||| S:5380 E:5386 ||| NNP
( ||| S:5386 E:5387 ||| -LRB-
Fig.  ||| S:5387 E:5392 ||| NNP
1B ||| S:5392 E:5394 ||| NNP
) ||| S:5394 E:5395 ||| -RRB-
.  ||| S:5395 E:5425 ||| .
MP-release  ||| S:5425 E:5436 ||| NNP
did  ||| S:5436 E:5440 ||| VBD
not  ||| S:5440 E:5444 ||| RB
correlate  ||| S:5444 E:5454 ||| VBN
with  ||| S:5454 E:5459 ||| IN
the  ||| S:5459 E:5463 ||| DT
level  ||| S:5463 E:5469 ||| NN
of  ||| S:5469 E:5472 ||| IN
cell  ||| S:5472 E:5487 ||| NN
apoptosis  ||| S:5487 E:5497 ||| NN
in  ||| S:5497 E:5500 ||| IN
HUVEC  ||| S:5500 E:5506 ||| NNP
stimulated  ||| S:5506 E:5517 ||| NN
with  ||| S:5517 E:5522 ||| IN
camptothecin  ||| S:5522 E:5545 ||| JJ
Phase  ||| S:5545 E:5551 ||| NN
contrast  ||| S:5551 E:5560 ||| NN
microscopy  ||| S:5560 E:5571 ||| NNS
showed  ||| S:5571 E:5578 ||| VBD
that  ||| S:5578 E:5583 ||| IN
HUVEC  ||| S:5583 E:5589 ||| NNP
culture  ||| S:5589 E:5607 ||| NN
treated  ||| S:5607 E:5615 ||| VBN
for  ||| S:5615 E:5619 ||| IN
24  ||| S:5619 E:5622 ||| CD
hrs  ||| S:5622 E:5626 ||| NN
with  ||| S:5626 E:5631 ||| IN
5  ||| S:5631 E:5633 ||| CD
μM  ||| S:5633 E:5636 ||| JJ
CPT  ||| S:5636 E:5640 ||| NNP
( ||| S:5640 E:5641 ||| -LRB-
Fig.  ||| S:5641 E:5646 ||| NNP
2C ||| S:5646 E:5648 ||| NNP
)  ||| S:5648 E:5650 ||| -RRB-
lost  ||| S:5650 E:5665 ||| VBD
confluence  ||| S:5665 E:5676 ||| VBN
with  ||| S:5676 E:5681 ||| IN
about  ||| S:5681 E:5687 ||| IN
30-40 ||| S:5687 E:5692 ||| CD
%  ||| S:5692 E:5694 ||| NN
cells  ||| S:5694 E:5700 ||| NNS
remaining  ||| S:5700 E:5710 ||| VBG
adherent ||| S:5710 E:5718 ||| NNS
.  ||| S:5718 E:5730 ||| .
The  ||| S:5730 E:5734 ||| DT
level  ||| S:5734 E:5740 ||| NN
of  ||| S:5740 E:5743 ||| IN
apoptosis  ||| S:5743 E:5753 ||| NN
of  ||| S:5753 E:5756 ||| IN
adherent  ||| S:5756 E:5765 ||| JJ
cells  ||| S:5765 E:5771 ||| NNS
was  ||| S:5771 E:5775 ||| VBD
assessed  ||| S:5775 E:5784 ||| VBN
by  ||| S:5784 E:5797 ||| IN
using  ||| S:5797 E:5803 ||| VBG
TUNEL  ||| S:5803 E:5809 ||| NNP
and  ||| S:5809 E:5813 ||| CC
annexin  ||| S:5813 E:5821 ||| FW
V-FITC ||| S:5821 E:5827 ||| FW
/  ||| S:5827 E:5829 ||| FW
propidium  ||| S:5829 E:5839 ||| FW
iodide  ||| S:5839 E:5846 ||| FW
assays  ||| S:5846 E:5863 ||| FW
( ||| S:5863 E:5864 ||| -LRB-
Fig  ||| S:5864 E:5868 ||| NNP
3 ||| S:5868 E:5869 ||| CD
) ||| S:5869 E:5870 ||| -RRB-
.  ||| S:5870 E:5872 ||| .
Approximately  ||| S:5872 E:5886 ||| RB
one  ||| S:5886 E:5890 ||| CD
third  ||| S:5890 E:5896 ||| JJ
of  ||| S:5896 E:5899 ||| IN
the  ||| S:5899 E:5903 ||| DT
remaining  ||| S:5903 E:5923 ||| JJ
adherent  ||| S:5923 E:5932 ||| JJ
cells  ||| S:5932 E:5938 ||| NNS
showed  ||| S:5938 E:5945 ||| VBD
annexin  ||| S:5945 E:5953 ||| JJ
V-binding  ||| S:5953 E:5963 ||| NN
( ||| S:5963 E:5964 ||| -LRB-
Fig.  ||| S:5964 E:5969 ||| NNP
3B ||| S:5969 E:5971 ||| NNP
)  ||| S:5971 E:5973 ||| -RRB-
and  ||| S:5973 E:5987 ||| CC
DNA-fragmentation  ||| S:5987 E:6005 ||| NNP
( ||| S:6005 E:6006 ||| -LRB-
TUNEL-positivity ||| S:6006 E:6022 ||| NNP
)  ||| S:6022 E:6024 ||| -RRB-
( ||| S:6024 E:6025 ||| -LRB-
Fig.  ||| S:6025 E:6030 ||| NNP
3C ||| S:6030 E:6032 ||| NNP
) ||| S:6032 E:6033 ||| -RRB-
.  ||| S:6033 E:6045 ||| .
Interestingly ||| S:6045 E:6058 ||| RB
,  ||| S:6058 E:6060 ||| ,
a  ||| S:6060 E:6062 ||| DT
ten  ||| S:6062 E:6066 ||| JJ
times  ||| S:6066 E:6072 ||| NNS
lower  ||| S:6072 E:6078 ||| JJR
concentration  ||| S:6078 E:6092 ||| NN
of  ||| S:6092 E:6095 ||| IN
CPT  ||| S:6095 E:6109 ||| NNP
( ||| S:6109 E:6110 ||| -LRB-
500  ||| S:6110 E:6114 ||| CD
nM ||| S:6114 E:6116 ||| NN
)  ||| S:6116 E:6118 ||| -RRB-
also  ||| S:6118 E:6123 ||| RB
induced  ||| S:6123 E:6131 ||| VBN
significant  ||| S:6131 E:6143 ||| JJ
MP-release  ||| S:6143 E:6154 ||| NN
after  ||| S:6154 E:6160 ||| IN
only  ||| S:6160 E:6165 ||| RB
4  ||| S:6165 E:6177 ||| CD
hrs  ||| S:6177 E:6181 ||| NN
of  ||| S:6181 E:6184 ||| IN
treatment  ||| S:6184 E:6194 ||| NN
( ||| S:6194 E:6195 ||| -LRB-
Fig.  ||| S:6195 E:6200 ||| NNP
3A ||| S:6200 E:6202 ||| NNP
)  ||| S:6202 E:6204 ||| -RRB-
and  ||| S:6204 E:6208 ||| CC
after  ||| S:6208 E:6214 ||| IN
24  ||| S:6214 E:6217 ||| CD
hrs ||| S:6217 E:6220 ||| NN
,  ||| S:6220 E:6222 ||| ,
500  ||| S:6222 E:6226 ||| CD
nM  ||| S:6226 E:6239 ||| JJ
camptothecin  ||| S:6239 E:6252 ||| NNS
induced  ||| S:6252 E:6260 ||| VBP
MP-release  ||| S:6260 E:6271 ||| JJ
comparable  ||| S:6271 E:6282 ||| JJ
to  ||| S:6282 E:6285 ||| TO
5  ||| S:6285 E:6287 ||| CD
μM  ||| S:6287 E:6290 ||| JJ
CPT  ||| S:6290 E:6304 ||| NNP
treatment ||| S:6304 E:6313 ||| NN
,  ||| S:6313 E:6315 ||| ,
but  ||| S:6315 E:6319 ||| CC
without  ||| S:6319 E:6327 ||| IN
any  ||| S:6327 E:6331 ||| DT
significant  ||| S:6331 E:6343 ||| JJ
increase  ||| S:6343 E:6352 ||| NN
in  ||| S:6352 E:6365 ||| IN
annexin  ||| S:6365 E:6373 ||| JJ
V-binding  ||| S:6373 E:6383 ||| JJ
to  ||| S:6383 E:6386 ||| TO
the  ||| S:6386 E:6390 ||| DT
cells  ||| S:6390 E:6396 ||| NNS
or  ||| S:6396 E:6399 ||| CC
DNA-fragmentation  ||| S:6399 E:6417 ||| NNP
( ||| S:6417 E:6418 ||| -LRB-
Fig.  ||| S:6418 E:6433 ||| NNP
3B ||| S:6433 E:6435 ||| NNP
, ||| S:6435 E:6436 ||| ,
3C ||| S:6436 E:6438 ||| CD
) ||| S:6438 E:6439 ||| -RRB-
.  ||| S:6439 E:6441 ||| .
The  ||| S:6441 E:6445 ||| DT
cell  ||| S:6445 E:6450 ||| NN
culture  ||| S:6450 E:6458 ||| NN
was  ||| S:6458 E:6462 ||| VBD
still  ||| S:6462 E:6468 ||| RB
confluent  ||| S:6468 E:6478 ||| JJ
( ||| S:6478 E:6479 ||| -LRB-
Fig.  ||| S:6479 E:6484 ||| NNP
2B ||| S:6484 E:6486 ||| NNP
)  ||| S:6486 E:6498 ||| -RRB-
with  ||| S:6498 E:6503 ||| IN
about  ||| S:6503 E:6509 ||| IN
20-30 ||| S:6509 E:6514 ||| CD
%  ||| S:6514 E:6516 ||| NN
lower  ||| S:6516 E:6522 ||| JJR
cell  ||| S:6522 E:6527 ||| NN
density  ||| S:6527 E:6535 ||| VBZ
as  ||| S:6535 E:6538 ||| RB
compared  ||| S:6538 E:6547 ||| VBN
with  ||| S:6547 E:6562 ||| IN
0.5 ||| S:6562 E:6565 ||| CD
%  ||| S:6565 E:6567 ||| NN
DMSO  ||| S:6567 E:6572 ||| NNP
treated  ||| S:6572 E:6580 ||| VBD
HUVEC  ||| S:6580 E:6586 ||| NNP
( ||| S:6586 E:6587 ||| -LRB-
Fig.  ||| S:6587 E:6592 ||| NNP
2A ||| S:6592 E:6594 ||| NNP
) ||| S:6594 E:6595 ||| -RRB-
.  ||| S:6595 E:6597 ||| .
This  ||| S:6597 E:6602 ||| DT
result  ||| S:6602 E:6609 ||| NN
indicates  ||| S:6609 E:6629 ||| VBZ
that  ||| S:6629 E:6634 ||| IN
MP-release  ||| S:6634 E:6645 ||| NNP
is  ||| S:6645 E:6648 ||| VBZ
not  ||| S:6648 E:6652 ||| RB
related  ||| S:6652 E:6660 ||| VBN
to  ||| S:6660 E:6663 ||| TO
cell  ||| S:6663 E:6668 ||| NN
desquamation ||| S:6668 E:6680 ||| NN
.  ||| S:6680 E:6682 ||| .
To  ||| S:6682 E:6695 ||| TO
investigate  ||| S:6695 E:6707 ||| VB
whether  ||| S:6707 E:6715 ||| IN
maturation  ||| S:6715 E:6726 ||| NN
of  ||| S:6726 E:6729 ||| IN
the  ||| S:6729 E:6733 ||| DT
cell  ||| S:6733 E:6738 ||| NN
culture  ||| S:6738 E:6756 ||| NN
influences  ||| S:6756 E:6767 ||| VBZ
the  ||| S:6767 E:6771 ||| DT
degree  ||| S:6771 E:6778 ||| NN
of  ||| S:6778 E:6781 ||| IN
MP-release  ||| S:6781 E:6792 ||| JJ
from  ||| S:6792 E:6797 ||| IN
HUVEC  ||| S:6797 E:6803 ||| NNP
in  ||| S:6803 E:6816 ||| IN
response  ||| S:6816 E:6825 ||| NN
to  ||| S:6825 E:6828 ||| TO
CPT ||| S:6828 E:6831 ||| NNP
,  ||| S:6831 E:6833 ||| ,
we  ||| S:6833 E:6836 ||| PRP
compared  ||| S:6836 E:6845 ||| VBD
MP-release  ||| S:6845 E:6856 ||| JJ
from  ||| S:6856 E:6861 ||| IN
subconfluent  ||| S:6861 E:6884 ||| JJ
HUVEC  ||| S:6884 E:6890 ||| NNP
( ||| S:6890 E:6891 ||| -LRB-
50 ||| S:6891 E:6893 ||| CD
%  ||| S:6893 E:6895 ||| NN
of  ||| S:6895 E:6898 ||| IN
confluence ||| S:6898 E:6908 ||| CD
)  ||| S:6908 E:6910 ||| -RRB-
at  ||| S:6910 E:6913 ||| IN
24  ||| S:6913 E:6916 ||| CD
hrs  ||| S:6916 E:6920 ||| NN
in  ||| S:6920 E:6923 ||| IN
culture ||| S:6923 E:6930 ||| NN
,  ||| S:6930 E:6932 ||| ,
HUVEC  ||| S:6932 E:6948 ||| NNP
reaching  ||| S:6948 E:6957 ||| VBG
confluence  ||| S:6957 E:6968 ||| NN
at  ||| S:6968 E:6971 ||| IN
48  ||| S:6971 E:6974 ||| CD
hrs  ||| S:6974 E:6978 ||| NN
in  ||| S:6978 E:6981 ||| IN
culture  ||| S:6981 E:6989 ||| NN
and  ||| S:6989 E:6993 ||| CC
overgrown  ||| S:6993 E:7013 ||| JJ
HUVEC  ||| S:7013 E:7019 ||| NN
at  ||| S:7019 E:7022 ||| IN
72  ||| S:7022 E:7025 ||| CD
hrs  ||| S:7025 E:7029 ||| NN
in  ||| S:7029 E:7032 ||| IN
culture ||| S:7032 E:7039 ||| NN
.  ||| S:7039 E:7041 ||| .
Our  ||| S:7041 E:7045 ||| PRP$
results  ||| S:7045 E:7053 ||| NNS
showed  ||| S:7053 E:7060 ||| VBD
that  ||| S:7060 E:7075 ||| DT
MP-release  ||| S:7075 E:7086 ||| JJ
in  ||| S:7086 E:7089 ||| IN
response  ||| S:7089 E:7098 ||| NN
to  ||| S:7098 E:7101 ||| TO
CPT  ||| S:7101 E:7105 ||| NNP
declined  ||| S:7105 E:7114 ||| VBD
with  ||| S:7114 E:7119 ||| IN
culture  ||| S:7119 E:7137 ||| NN
maturation ||| S:7137 E:7147 ||| NN
.  ||| S:7147 E:7149 ||| .
There  ||| S:7149 E:7155 ||| EX
was  ||| S:7155 E:7159 ||| VBD
also  ||| S:7159 E:7164 ||| RB
a  ||| S:7164 E:7166 ||| DT
change  ||| S:7166 E:7173 ||| NN
of  ||| S:7173 E:7176 ||| IN
the  ||| S:7176 E:7180 ||| DT
sensitivity  ||| S:7180 E:7192 ||| NN
of  ||| S:7192 E:7205 ||| IN
overgrown  ||| S:7205 E:7215 ||| JJ
HUVEC  ||| S:7215 E:7221 ||| NN
to  ||| S:7221 E:7224 ||| TO
CPT  ||| S:7224 E:7228 ||| NNP
treatment  ||| S:7228 E:7238 ||| NN
in  ||| S:7238 E:7241 ||| IN
confluent  ||| S:7241 E:7251 ||| CD
72  ||| S:7251 E:7254 ||| CD
hrs  ||| S:7254 E:7258 ||| CD
old  ||| S:7258 E:7272 ||| JJ
culture  ||| S:7272 E:7280 ||| NN
resulting  ||| S:7280 E:7290 ||| VBG
in  ||| S:7290 E:7293 ||| IN
the  ||| S:7293 E:7297 ||| DT
higher  ||| S:7297 E:7304 ||| JJR
concentration  ||| S:7304 E:7318 ||| NN
of  ||| S:7318 E:7321 ||| IN
CPT  ||| S:7321 E:7325 ||| NNP
( ||| S:7325 E:7326 ||| -LRB-
5  ||| S:7326 E:7338 ||| CD
μM ||| S:7338 E:7340 ||| NN
)  ||| S:7340 E:7342 ||| -RRB-
releasing  ||| S:7342 E:7352 ||| VBG
higher  ||| S:7352 E:7359 ||| JJR
levels  ||| S:7359 E:7366 ||| NNS
of  ||| S:7366 E:7369 ||| IN
MP  ||| S:7369 E:7372 ||| NNP
( ||| S:7372 E:7373 ||| -LRB-
Fig.  ||| S:7373 E:7378 ||| CD
4 ||| S:7378 E:7379 ||| CD
) ||| S:7379 E:7380 ||| -RRB-
.  ||| S:7380 E:7382 ||| .
In  ||| S:7382 E:7385 ||| IN
growing  ||| S:7385 E:7403 ||| VBG
culture  ||| S:7403 E:7411 ||| NN
at  ||| S:7411 E:7414 ||| IN
24  ||| S:7414 E:7417 ||| CD
hrs ||| S:7417 E:7420 ||| NN
,  ||| S:7420 E:7422 ||| ,
500  ||| S:7422 E:7426 ||| CD
nM  ||| S:7426 E:7429 ||| JJ
CPT  ||| S:7429 E:7433 ||| NNP
caused  ||| S:7433 E:7440 ||| VBD
even  ||| S:7440 E:7445 ||| RB
higher  ||| S:7445 E:7462 ||| JJR
MP-release  ||| S:7462 E:7473 ||| NN
than  ||| S:7473 E:7478 ||| IN
5  ||| S:7478 E:7480 ||| CD
μM  ||| S:7480 E:7483 ||| JJ
CPT ||| S:7483 E:7486 ||| NNP
.  ||| S:7486 E:7488 ||| .
In  ||| S:7488 E:7491 ||| IN
confluent  ||| S:7491 E:7501 ||| JJ
HUVEC  ||| S:7501 E:7507 ||| NNP
48  ||| S:7507 E:7510 ||| CD
hrs  ||| S:7510 E:7514 ||| CD
old ||| S:7514 E:7517 ||| JJ
,  ||| S:7517 E:7529 ||| ,
the  ||| S:7529 E:7533 ||| DT
MP-release  ||| S:7533 E:7544 ||| JJ
induced  ||| S:7544 E:7552 ||| NN
by  ||| S:7552 E:7555 ||| IN
500  ||| S:7555 E:7559 ||| CD
nM  ||| S:7559 E:7562 ||| JJ
and  ||| S:7562 E:7566 ||| CC
5  ||| S:7566 E:7568 ||| CD
μM  ||| S:7568 E:7571 ||| JJ
CPT  ||| S:7571 E:7575 ||| NNP
was  ||| S:7575 E:7579 ||| VBD
not  ||| S:7579 E:7593 ||| RB
significantly  ||| S:7593 E:7607 ||| RB
different  ||| S:7607 E:7617 ||| JJ
( ||| S:7617 E:7618 ||| -LRB-
Fig.  ||| S:7618 E:7623 ||| CD
4 ||| S:7623 E:7624 ||| CD
) ||| S:7624 E:7625 ||| -RRB-
.  ||| S:7625 E:7655 ||| .
Endothelial  ||| S:7655 E:7667 ||| JJ
antigens  ||| S:7667 E:7676 ||| JJ
CD  ||| S:7676 E:7679 ||| NN
105  ||| S:7679 E:7683 ||| CD
and  ||| S:7683 E:7687 ||| CC
CD  ||| S:7687 E:7690 ||| NNP
59  ||| S:7690 E:7693 ||| CD
were  ||| S:7693 E:7698 ||| VBD
both  ||| S:7698 E:7713 ||| DT
expressed  ||| S:7713 E:7723 ||| VBN
on  ||| S:7723 E:7726 ||| IN
living  ||| S:7726 E:7733 ||| VBG
cells ||| S:7733 E:7738 ||| NNS
,  ||| S:7738 E:7740 ||| ,
apoptotic  ||| S:7740 E:7750 ||| JJ
bodies  ||| S:7750 E:7757 ||| NNS
and  ||| S:7757 E:7761 ||| CC
other  ||| S:7761 E:7777 ||| JJ
cell  ||| S:7777 E:7782 ||| NN
fragments  ||| S:7782 E:7792 ||| NNS
in  ||| S:7792 E:7795 ||| IN
CPT  ||| S:7795 E:7799 ||| NNP
treated  ||| S:7799 E:7807 ||| VBD
HUVEC  ||| S:7807 E:7813 ||| NNP
culture  ||| S:7813 E:7821 ||| NN
but  ||| S:7821 E:7825 ||| CC
CD  ||| S:7825 E:7828 ||| NNP
105  ||| S:7828 E:7842 ||| CD
was  ||| S:7842 E:7846 ||| VBD
absent  ||| S:7846 E:7853 ||| VBN
on  ||| S:7853 E:7856 ||| IN
50 ||| S:7856 E:7858 ||| CD
%  ||| S:7858 E:7860 ||| NN
of  ||| S:7860 E:7863 ||| IN
annexin  ||| S:7863 E:7871 ||| JJ
V-binding  ||| S:7871 E:7881 ||| JJ
membrane  ||| S:7881 E:7900 ||| NNS
microparticles  ||| S:7900 E:7925 ||| VBP
Using  ||| S:7925 E:7931 ||| VBG
flow  ||| S:7931 E:7936 ||| NN
cytometry ||| S:7936 E:7945 ||| NN
,  ||| S:7945 E:7947 ||| ,
in  ||| S:7947 E:7950 ||| IN
SSC  ||| S:7950 E:7954 ||| NNP
vs.  ||| S:7954 E:7958 ||| FW
FSC  ||| S:7958 E:7962 ||| FW
plot  ||| S:7962 E:7967 ||| FW
we  ||| S:7967 E:7970 ||| FW
gated  ||| S:7970 E:7986 ||| FW
homogeneous  ||| S:7986 E:7998 ||| FW
population  ||| S:7998 E:8009 ||| NN
of  ||| S:8009 E:8012 ||| IN
single  ||| S:8012 E:8019 ||| JJ
living  ||| S:8019 E:8026 ||| NN
cells  ||| S:8026 E:8032 ||| NNS
( ||| S:8032 E:8033 ||| -LRB-
G1  ||| S:8033 E:8036 ||| NNP
on  ||| S:8036 E:8039 ||| IN
Fig.  ||| S:8039 E:8054 ||| CD
5A ||| S:8054 E:8056 ||| CD
) ||| S:8056 E:8057 ||| -RRB-
,  ||| S:8057 E:8059 ||| ,
which  ||| S:8059 E:8065 ||| WDT
appeared  ||| S:8065 E:8074 ||| VBD
negative  ||| S:8074 E:8083 ||| JJ
in  ||| S:8083 E:8086 ||| IN
propidium  ||| S:8086 E:8096 ||| FW
iodide  ||| S:8096 E:8103 ||| FW
staining  ||| S:8103 E:8122 ||| FW
( ||| S:8122 E:8123 ||| -LRB-
Fig.  ||| S:8123 E:8128 ||| NNP
5B ||| S:8128 E:8130 ||| NNP
) ||| S:8130 E:8131 ||| -RRB-
.  ||| S:8131 E:8133 ||| .
Living  ||| S:8133 E:8140 ||| VBG
cells  ||| S:8140 E:8146 ||| NNS
from  ||| S:8146 E:8151 ||| IN
control  ||| S:8151 E:8159 ||| NN
cultures  ||| S:8159 E:8168 ||| NNS
as  ||| S:8168 E:8171 ||| IN
well  ||| S:8171 E:8176 ||| RB
as  ||| S:8176 E:8189 ||| RB
from  ||| S:8189 E:8194 ||| IN
cultures  ||| S:8194 E:8203 ||| NNS
treated  ||| S:8203 E:8211 ||| VBN
with  ||| S:8211 E:8216 ||| IN
CPT  ||| S:8216 E:8220 ||| NNP
were  ||| S:8220 E:8225 ||| VBD
strongly  ||| S:8225 E:8234 ||| RB
positive  ||| S:8234 E:8243 ||| JJ
for  ||| S:8243 E:8257 ||| IN
both  ||| S:8257 E:8262 ||| DT
antigens  ||| S:8262 E:8271 ||| JJ
CD  ||| S:8271 E:8274 ||| NN
105  ||| S:8274 E:8278 ||| CD
and  ||| S:8278 E:8282 ||| CC
CD  ||| S:8282 E:8285 ||| NNP
59  ||| S:8285 E:8288 ||| CD
( ||| S:8288 E:8289 ||| -LRB-
Fig.  ||| S:8289 E:8294 ||| NNP
5C ||| S:8294 E:8296 ||| NNP
) ||| S:8296 E:8297 ||| -RRB-
.  ||| S:8297 E:8299 ||| .
Expression  ||| S:8299 E:8310 ||| NN
of  ||| S:8310 E:8323 ||| IN
CD59  ||| S:8323 E:8328 ||| CD
on  ||| S:8328 E:8331 ||| IN
endothelial  ||| S:8331 E:8343 ||| JJ
cells  ||| S:8343 E:8349 ||| NNS
was  ||| S:8349 E:8353 ||| VBD
not  ||| S:8353 E:8357 ||| RB
influenced  ||| S:8357 E:8368 ||| VBN
by  ||| S:8368 E:8371 ||| IN
24  ||| S:8371 E:8374 ||| CD
hrs  ||| S:8374 E:8388 ||| JJ
incubation  ||| S:8388 E:8399 ||| NN
with  ||| S:8399 E:8404 ||| IN
500nM  ||| S:8404 E:8410 ||| NNP
or  ||| S:8410 E:8413 ||| CC
5μM  ||| S:8413 E:8417 ||| NNP
CPT  ||| S:8417 E:8421 ||| NNP
as  ||| S:8421 E:8424 ||| RB
compared  ||| S:8424 E:8433 ||| VBN
with  ||| S:8433 E:8438 ||| IN
control  ||| S:8438 E:8456 ||| NN
cells  ||| S:8456 E:8462 ||| NNS
incubated  ||| S:8462 E:8472 ||| VBN
with  ||| S:8472 E:8477 ||| IN
0.5 ||| S:8477 E:8480 ||| CD
%  ||| S:8480 E:8482 ||| NN
DMSO ||| S:8482 E:8486 ||| NNP
.  ||| S:8486 E:8488 ||| .
Expression  ||| S:8488 E:8499 ||| NN
of  ||| S:8499 E:8502 ||| IN
CD105  ||| S:8502 E:8508 ||| NNP
was  ||| S:8508 E:8522 ||| VBD
only  ||| S:8522 E:8527 ||| RB
slightly  ||| S:8527 E:8536 ||| RB
decreased  ||| S:8536 E:8546 ||| VBN
on  ||| S:8546 E:8549 ||| IN
CPT  ||| S:8549 E:8553 ||| NNP
treated  ||| S:8553 E:8561 ||| VBD
cells ||| S:8561 E:8566 ||| NNS
.  ||| S:8566 E:8568 ||| .
Cell  ||| S:8568 E:8583 ||| NN
fragments  ||| S:8583 E:8593 ||| VBZ
>  ||| S:8593 E:8595 ||| CD
4  ||| S:8595 E:8597 ||| CD
μm  ||| S:8597 E:8600 ||| NN
in  ||| S:8600 E:8603 ||| IN
size  ||| S:8603 E:8608 ||| NN
as  ||| S:8608 E:8611 ||| IN
compared  ||| S:8611 E:8620 ||| VBN
with  ||| S:8620 E:8625 ||| IN
standard  ||| S:8625 E:8644 ||| JJ
beads  ||| S:8644 E:8650 ||| NN
were  ||| S:8650 E:8655 ||| VBD
gated  ||| S:8655 E:8661 ||| VBN
separately  ||| S:8661 E:8672 ||| RB
( ||| S:8672 E:8673 ||| -LRB-
G2  ||| S:8673 E:8676 ||| NNP
on  ||| S:8676 E:8679 ||| IN
Fig.  ||| S:8679 E:8684 ||| CD
5A ||| S:8684 E:8686 ||| CD
) ||| S:8686 E:8687 ||| -RRB-
.  ||| S:8687 E:8689 ||| .
Larger  ||| S:8689 E:8696 ||| JJR
cell  ||| S:8696 E:8711 ||| NN
fragments  ||| S:8711 E:8721 ||| NNS
appeared  ||| S:8721 E:8730 ||| VBD
positive  ||| S:8730 E:8739 ||| JJ
in  ||| S:8739 E:8742 ||| IN
propidium  ||| S:8742 E:8752 ||| FW
iodide  ||| S:8752 E:8759 ||| FW
staining  ||| S:8759 E:8778 ||| FW
( ||| S:8778 E:8779 ||| -LRB-
Fig.  ||| S:8779 E:8784 ||| NNP
5B ||| S:8784 E:8786 ||| NNP
) ||| S:8786 E:8787 ||| -RRB-
.  ||| S:8787 E:8789 ||| .
All  ||| S:8789 E:8793 ||| DT
analyzed  ||| S:8793 E:8802 ||| JJ
cell  ||| S:8802 E:8807 ||| NN
fragments  ||| S:8807 E:8817 ||| NNS
were  ||| S:8817 E:8822 ||| VBD
positive  ||| S:8822 E:8831 ||| JJ
for  ||| S:8831 E:8845 ||| IN
CD59  ||| S:8845 E:8850 ||| NNP
and  ||| S:8850 E:8854 ||| CC
also  ||| S:8854 E:8859 ||| RB
expressed  ||| S:8859 E:8869 ||| VBD
CD  ||| S:8869 E:8872 ||| NNP
105  ||| S:8872 E:8876 ||| CD
( ||| S:8876 E:8877 ||| -LRB-
Fig.  ||| S:8877 E:8882 ||| NNP
5D ||| S:8882 E:8884 ||| NNP
) ||| S:8884 E:8885 ||| -RRB-
.  ||| S:8885 E:8887 ||| .
Comparison  ||| S:8887 E:8898 ||| NN
of  ||| S:8898 E:8911 ||| IN
areas  ||| S:8911 E:8917 ||| NNS
under  ||| S:8917 E:8923 ||| IN
the  ||| S:8923 E:8927 ||| DT
different  ||| S:8927 E:8937 ||| JJ
peaks  ||| S:8937 E:8943 ||| NNS
on  ||| S:8943 E:8946 ||| IN
the  ||| S:8946 E:8950 ||| DT
histogram  ||| S:8950 E:8960 ||| NN
( ||| S:8960 E:8961 ||| -LRB-
Fig.  ||| S:8961 E:8976 ||| NNP
5C ||| S:8976 E:8978 ||| NNP
, ||| S:8978 E:8979 ||| ,
5D ||| S:8979 E:8981 ||| CD
)  ||| S:8981 E:8983 ||| -RRB-
indicates  ||| S:8983 E:8993 ||| VBZ
that  ||| S:8993 E:8998 ||| IN
the  ||| S:8998 E:9002 ||| DT
portion  ||| S:9002 E:9010 ||| NN
of  ||| S:9010 E:9013 ||| IN
cell  ||| S:9013 E:9018 ||| NN
fragments  ||| S:9018 E:9038 ||| VBZ
corresponding  ||| S:9038 E:9052 ||| JJ
to  ||| S:9052 E:9055 ||| TO
apoptotic  ||| S:9055 E:9065 ||| VB
bodies  ||| S:9065 E:9072 ||| NNS
and  ||| S:9072 E:9076 ||| CC
necrotic  ||| S:9076 E:9085 ||| JJ
cells  ||| S:9085 E:9091 ||| NNS
was  ||| S:9091 E:9105 ||| VBD
significantly  ||| S:9105 E:9119 ||| RB
higher  ||| S:9119 E:9126 ||| JJR
in  ||| S:9126 E:9129 ||| IN
culture  ||| S:9129 E:9137 ||| NN
treated  ||| S:9137 E:9145 ||| VBN
with  ||| S:9145 E:9150 ||| IN
5  ||| S:9150 E:9152 ||| CD
μM  ||| S:9152 E:9155 ||| JJ
CPT  ||| S:9155 E:9159 ||| NNP
as  ||| S:9159 E:9172 ||| RB
compared  ||| S:9172 E:9181 ||| VBN
to  ||| S:9181 E:9184 ||| TO
culture  ||| S:9184 E:9192 ||| VB
treated  ||| S:9192 E:9200 ||| VBN
with  ||| S:9200 E:9205 ||| IN
500  ||| S:9205 E:9209 ||| CD
nM  ||| S:9209 E:9212 ||| JJ
CPT  ||| S:9212 E:9216 ||| NNP
or  ||| S:9216 E:9219 ||| CC
with  ||| S:9219 E:9224 ||| IN
0.5 ||| S:9224 E:9227 ||| CD
%  ||| S:9227 E:9239 ||| NN
DMSO  ||| S:9239 E:9244 ||| NNP
alone ||| S:9244 E:9249 ||| RB
.  ||| S:9249 E:9251 ||| .
In  ||| S:9251 E:9254 ||| IN
a  ||| S:9254 E:9256 ||| DT
separate  ||| S:9256 E:9265 ||| JJ
protocol  ||| S:9265 E:9274 ||| NN
we  ||| S:9274 E:9277 ||| PRP
analyzed  ||| S:9277 E:9286 ||| VBD
the  ||| S:9286 E:9300 ||| DT
expression  ||| S:9300 E:9311 ||| NN
of  ||| S:9311 E:9314 ||| IN
CD  ||| S:9314 E:9317 ||| NNP
59  ||| S:9317 E:9320 ||| CD
and  ||| S:9320 E:9324 ||| CC
CD  ||| S:9324 E:9327 ||| NNP
105  ||| S:9327 E:9331 ||| CD
on  ||| S:9331 E:9334 ||| IN
membrane  ||| S:9334 E:9343 ||| JJ
MP ||| S:9343 E:9345 ||| NNP
.  ||| S:9345 E:9347 ||| .
Comparison  ||| S:9347 E:9368 ||| NN
of  ||| S:9368 E:9371 ||| IN
FSC  ||| S:9371 E:9375 ||| NNP
values  ||| S:9375 E:9382 ||| NNS
of  ||| S:9382 E:9385 ||| IN
standard  ||| S:9385 E:9394 ||| JJ
beads  ||| S:9394 E:9400 ||| NN
and  ||| S:9400 E:9404 ||| CC
analyzed  ||| S:9404 E:9413 ||| VBD
MP  ||| S:9413 E:9416 ||| NNP
showed  ||| S:9416 E:9433 ||| VBD
that  ||| S:9433 E:9438 ||| IN
95 ||| S:9438 E:9440 ||| CD
%  ||| S:9440 E:9442 ||| NN
of  ||| S:9442 E:9445 ||| IN
annexin  ||| S:9445 E:9453 ||| JJ
V-binding  ||| S:9453 E:9463 ||| JJ
MP  ||| S:9463 E:9466 ||| NNP
released  ||| S:9466 E:9475 ||| VBD
from  ||| S:9475 E:9480 ||| IN
HUVEC  ||| S:9480 E:9486 ||| NNP
were  ||| S:9486 E:9494 ||| VBD
